- Home
- BC vs PTGX Comparison
BC vs PTGX Comparison
Compare BC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BC
- PTGX
- Stock Information
- Founded
- BC 1845
- PTGX 2006
- Country
- BC United States
- PTGX United States
- Employees
- BC N/A
- PTGX N/A
- Industry
- BC Homebuilding
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- BC Consumer Discretionary
- PTGX Health Care
- Exchange
- BC Nasdaq
- PTGX Nasdaq
- Market Cap
- BC 3.6B
- PTGX 4.0B
- IPO Year
- BC N/A
- PTGX 2016
- Fundamental
- Price
- BC $62.92
- PTGX $66.47
- Analyst Decision
- BC Buy
- PTGX Strong Buy
- Analyst Count
- BC 13
- PTGX 8
- Target Price
- BC $65.23
- PTGX $71.13
- AVG Volume (30 Days)
- BC 696.2K
- PTGX 1.0M
- Earning Date
- BC 10-23-2025
- PTGX 11-06-2025
- Dividend Yield
- BC 2.70%
- PTGX N/A
- EPS Growth
- BC N/A
- PTGX N/A
- EPS
- BC 0.63
- PTGX 0.80
- Revenue
- BC $5,097,000,000.00
- PTGX $209,180,000.00
- Revenue This Year
- BC $1.58
- PTGX N/A
- Revenue Next Year
- BC $4.59
- PTGX $243.08
- P/E Ratio
- BC $101.36
- PTGX $81.13
- Revenue Growth
- BC N/A
- PTGX N/A
- 52 Week Low
- BC $41.00
- PTGX $33.31
- 52 Week High
- BC $87.65
- PTGX $68.26
- Technical
- Relative Strength Index (RSI)
- BC N/A
- PTGX 61.99
- Support Level
- BC N/A
- PTGX $62.24
- Resistance Level
- BC N/A
- PTGX $66.87
- Average True Range (ATR)
- BC 0.00
- PTGX 2.34
- MACD
- BC 0.00
- PTGX -0.16
- Stochastic Oscillator
- BC 0.00
- PTGX 69.26
About BC Brunswick Corporation
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.